{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T12:11:04Z","timestamp":1759493464468,"version":"build-2065373602"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Jilin Province Department of Finance, China","award":["20200401007MH"],"award-info":[{"award-number":["20200401007MH"]}]},{"name":"the Science and Technology Department of Jilin Province, China","award":["20200401007MH"],"award-info":[{"award-number":["20200401007MH"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Complement Med Ther"],"DOI":"10.1186\/s12906-025-05112-5","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:36:53Z","timestamp":1759491413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-marketing safety evaluation of Guhong Injection: a multicenter, prospective real-world study of 30,000 cases in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Jiayu","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianzi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"5112_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116383","volume":"309","author":"A Choudhury","year":"2023","unstructured":"Choudhury A, Singh PA, Bajwa N, Dash S, Bisht P. Pharmacovigilance of herbal medicines: concerns and future prospects. J Ethnopharmacol. 2023;309:116383.","journal-title":"J Ethnopharmacol"},{"issue":"12","key":"5112_CR2","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1080\/03007995.2020.1832056","volume":"36","author":"Y He","year":"2020","unstructured":"He Y, Gao XM, Li L, Liu XG, Liu W, Hong XJ, et al. Safety of the Xuesaitong injection in china: results from a large-scale multicentre post-marketing surveillance study in a real-world setting. Curr Med Res Opin. 2020;36(12):1947\u201353.","journal-title":"Curr Med Res Opin"},{"key":"5112_CR3","doi-asserted-by":"crossref","unstructured":"Li XL, Tang JF, Li WX, Li CX, Zhao T, Zhao BC, Wang Y, Zhang H, Chen XF, Xu T et al. Postmarketing Safety Surveillance and Reevaluation of Danhong Injection: Clinical Study of 30888 Cases. Evid Based Complement Alternat Med 2015, 2015:610846.","DOI":"10.1155\/2015\/610846"},{"issue":"1","key":"5112_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13063-019-3990-3","volume":"21","author":"Z Jieqin","year":"2020","unstructured":"Jieqin Z, Shuling L, Hairong C, Xingzhen D, Yanhong C, Zilin J, Bojun C. Efficacy and safety of Guhong injection for treating coronary microvascular disease: study protocol for a randomized controlled trial. Trials. 2020;21(1):75.","journal-title":"Trials"},{"key":"5112_CR5","doi-asserted-by":"publisher","first-page":"1010533","DOI":"10.3389\/fphar.2022.1010533","volume":"13","author":"L Li","year":"2022","unstructured":"Li L, Shao C, Liu Z, Wu X, Yang J, Wan H. Comparative efficacy of Honghua class injections for treating acute ischemic stroke: a bayesian network meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:1010533.","journal-title":"Front Pharmacol"},{"issue":"21","key":"5112_CR6","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.12998\/wjcc.v10.i21.7265","volume":"10","author":"WW Zhang","year":"2022","unstructured":"Zhang WW, Xin J, Zhang GY, Zhai QJ, Zhang HM, Wu CS. Efficacy of Guhong injection versus butylphthalide and sodium chloride injection for mild ischemic stroke: a multicenter controlled study. World J Clin Cases. 2022;10(21):7265\u201374.","journal-title":"World J Clin Cases"},{"key":"5112_CR7","doi-asserted-by":"publisher","first-page":"1019795","DOI":"10.3389\/fphar.2022.1019795","volume":"13","author":"S Li","year":"2022","unstructured":"Li S, Huang L, Zeng L, Yu D, Jia ZJ, Cheng G, Zhang L. A tool for screening potentially inappropriate prescribing in Chinese children. Front Pharmacol. 2022;13:1019795.","journal-title":"Front Pharmacol"},{"issue":"1","key":"5112_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13020-023-00718-8","volume":"18","author":"R Zheng","year":"2023","unstructured":"Zheng R, Chen Z, Guan Z, Zhao C, Cui H, Shang H. Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection. Chin Med. 2023;18(1):15.","journal-title":"Chin Med"},{"issue":"5","key":"5112_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40264-016-0502-1","volume":"40","author":"T Schutte","year":"2017","unstructured":"Schutte T, Tichelaar J, Reumerman MO, van Eekeren R, Rolfes L, van Puijenbroek EP, et al. Feasibility and educational value of a student-run pharmacovigilance programme: a prospective cohort study. Drug Saf. 2017;40(5):409\u201318.","journal-title":"Drug Saf"},{"key":"5112_CR10","doi-asserted-by":"publisher","first-page":"756207","DOI":"10.3389\/fphar.2021.756207","volume":"12","author":"X Nie","year":"2021","unstructured":"Nie X, Jia L, Peng X, Zhao H, Yu Y, Chen Z, et al. Detection of drug-induced thrombocytopenia signals in children using routine electronic medical records. Front Pharmacol. 2021;12:756207.","journal-title":"Front Pharmacol"},{"issue":"1","key":"5112_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13020-022-00617-4","volume":"17","author":"Z Chen","year":"2022","unstructured":"Chen Z, Zhao M, You L, Zheng R, Jiang Y, Zhang X, et al. Developing an artificial intelligence method for screening hepatotoxic compounds in traditional Chinese medicine and western medicine combination. Chin Med. 2022;17(1):58.","journal-title":"Chin Med"},{"key":"5112_CR12","doi-asserted-by":"publisher","first-page":"1261326","DOI":"10.3389\/fphar.2023.1261326","volume":"14","author":"Q Wang","year":"2023","unstructured":"Wang Q, Yang Z, Guo L, Li Z, Liu Y, Feng S, et al. Chemical composition, pharmacology and pharmacokinetic studies of Guhong injection in the treatment of ischemic stroke. Front Pharmacol. 2023;14:1261326.","journal-title":"Front Pharmacol"},{"issue":"6","key":"5112_CR13","first-page":"954","volume":"35","author":"Y He","year":"2015","unstructured":"He Y, Zhou H, Hunag L, Zhao T, Fu W, Wan H. Simultaneous quantification of seven components in Guhong injection by HPLC-DAD. Chin J Pharm Anal. 2015;35(6):954\u20139.","journal-title":"Chin J Pharm Anal"},{"key":"5112_CR14","doi-asserted-by":"publisher","first-page":"154034","DOI":"10.1016\/j.phymed.2022.154034","volume":"99","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wu H, Han Z, Sheng H, Wu Y, Wang Y, Guo X, Zhu Y, Li X, Wang Y. Guhong injection promotes post-stroke functional recovery via attenuating cortical inflammation and apoptosis in subacute stage of ischemic stroke. Phytomedicine. 2022;99:154034.","journal-title":"Phytomedicine"},{"key":"5112_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113744","volume":"155","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wu H, Sheng H, Wang Y, Li X, Wang Y, et al. Discovery of anti-stroke active substances in Guhong injection based on multi-phenotypic screening of zebrafish. Biomed Pharmacother. 2022;155:113744.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5112_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jep.2013.10.050","volume":"151","author":"X Zhou","year":"2014","unstructured":"Zhou X, Tang L, Xu Y, Zhou G, Wang Z. Towards a better understanding of medicinal uses of Carthamus tinctorius L. in traditional Chinese medicine: a phytochemical and pharmacological review. J Ethnopharmacol. 2014;151(1):27\u201343.","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"5112_CR17","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/j.1365-2621.2002.tb11415.x","volume":"67","author":"MK Snowden","year":"2002","unstructured":"Snowden MK, Baxter JH, Mamula Bergana M, Reyzer I, Pound V. Stability of N-acetylglutamine and glutamine in aqueous solution and in a liquid nutritional product by an improved HPLC method. J Food Sci. 2002;67(1):384\u20139.","journal-title":"J Food Sci"},{"issue":"9","key":"5112_CR18","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/cns.13184","volume":"25","author":"LL Luo","year":"2019","unstructured":"Luo LL, Li YF, Shan HM, Wang LP, Yuan F, Ma YY, et al. L-glutamine protects mouse brain from ischemic injury via up-regulating heat shock protein 70. CNS Neurosci Ther. 2019;25(9):1030\u201341.","journal-title":"CNS Neurosci Ther"},{"issue":"3","key":"5112_CR19","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s10620-006-9500-y","volume":"52","author":"JM Lopez-Pedrosa","year":"2007","unstructured":"Lopez-Pedrosa JM, Manzano M, Baxter JH, Rueda R. N-acetyl-L-glutamine, a liquid-stable source of glutamine, partially prevents changes in body weight and on intestinal immunity induced by protein energy malnutrition in pigs. Dig Dis Sci. 2007;52(3):650\u20138.","journal-title":"Dig Dis Sci"},{"key":"5112_CR20","doi-asserted-by":"publisher","first-page":"761097","DOI":"10.3389\/fphar.2022.761097","volume":"13","author":"Z Yan","year":"2022","unstructured":"Yan Z, Feng Z, Jiao Z, Wang G, Chen C, Feng D. Safety of using traditional Chinese medicine injections in primary medical institutions: based on the spontaneous reporting system 2016\u20132020 in Henan province, China. Front Pharmacol. 2022;13:761097.","journal-title":"Front Pharmacol"},{"issue":"1","key":"5112_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13020-022-00681-w","volume":"17","author":"W Zheng","year":"2022","unstructured":"Zheng W, Wu Y, Gao H, Ouyang D. Traditional Chinese medicine injections: where we are after 80-year development. Chin Med. 2022;17(1):127.","journal-title":"Chin Med"},{"issue":"2","key":"5112_CR22","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/bcp.15277","volume":"89","author":"H Song","year":"2023","unstructured":"Song H, Pei X, Liu Z, Shen C, Sun J, Liu Y, et al. Pharmacovigilance in China: evolution and future challenges. Br J Clin Pharmacol. 2023;89(2):510\u201322.","journal-title":"Br J Clin Pharmacol"},{"key":"5112_CR23","doi-asserted-by":"publisher","first-page":"1541005","DOI":"10.3389\/fphar.2025.1541005","volume":"16","author":"L Duan","year":"2025","unstructured":"Duan L, An F, Tian C, Yan W, Chen J, Zhang H, et al. Post-marketing safety re-evaluation of placental peptide injection in China: a large-scale multicenter real-world study. Front Pharmacol. 2025;16:1541005.","journal-title":"Front Pharmacol"},{"key":"5112_CR24","volume-title":"Guidelines for Preparing core Clinical-safety information on drugs: report of CIOMS working groups III and V: including new proposals for","author":"Sciences CfIOoM","year":"1999","unstructured":"Sciences CfIOoM. Guidelines for Preparing core Clinical-safety information on drugs: report of CIOMS working groups III and V: including new proposals for. Investigator\u2019s Brochures: CIOMS; 1999."},{"issue":"1","key":"5112_CR25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13020-021-00433-2","volume":"16","author":"Z Liang","year":"2021","unstructured":"Liang Z, Lai Y, Li M, Shi J, Lei CI, Hu H, et al. Applying regulatory science in traditional Chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications. Chin Med. 2021;16(1):23.","journal-title":"Chin Med"},{"issue":"13","key":"5112_CR26","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1001\/jama.1983.03330370053031","volume":"249","author":"JA Hanley","year":"1983","unstructured":"Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA. 1983;249(13):1743\u20135.","journal-title":"JAMA"},{"issue":"20","key":"5112_CR27","first-page":"5024","volume":"45","author":"J Xin-Yao","year":"2020","unstructured":"Xin-Yao J, Ke-Yi W, Jing-Bo Z, Chun-Xiang L, Hui W, Zhi L, Wen-Tai P, Hu-Cheng W, Nan LI, Hui-Zi C, et al. [Analysis of injection of Xuesaitong (lyophilized) in 30097 cases in real world]. Zhongguo Zhong Yao Za Zhi. 2020;45(20):5024\u20138.","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"issue":"12","key":"5112_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad606","volume":"10","author":"SW Sunagawa","year":"2023","unstructured":"Sunagawa SW, Arduser S, Miller MM, Lyden E, LeMaster M, Cortes-Penfield N, et al. Serious adverse events and laboratory monitoring regimens for outpatient parenteral antimicrobial therapy with cefazolin and ceftriaxone. Open Forum Infect Dis. 2023;10(12):ofad606.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"5112_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/cid\/cix733","volume":"66","author":"SC Keller","year":"2018","unstructured":"Keller SC, Williams D, Gavgani M, Hirsch D, Adamovich J, Hohl D, Gurses AP, Cosgrove SE. Rates of and risk factors for adverse drug events in outpatient parenteral antimicrobial therapy. Clin Infect Dis. 2018;66(1):11\u20139.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Complementary Medicine and Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05112-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12906-025-05112-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12906-025-05112-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:36:58Z","timestamp":1759491418000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccomplementalternmed.biomedcentral.com\/articles\/10.1186\/s12906-025-05112-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5112"],"URL":"https:\/\/doi.org\/10.1186\/s12906-025-05112-5","relation":{},"ISSN":["2662-7671"],"issn-type":[{"value":"2662-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki. It was approved by the Ethics Committee of The First Hospital of Jilin University (19K126-001) and registered on the Chinese Clinical Trial Registry website (, ChiCTR2000031123). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Guhong Injection (Approval Document No.: National Medicine Permit No. H22026638) was produced by Tonghua Guhong Pharmaceutical Co., Ltd (Tonghua, China). The current study was financially supported by Tonghua Guhong Pharmaceutical Co., Ltd. as part of Grant 20200401007MH. The authors declare that Tonghua Guhong Pharmaceutical Co., Ltd. was not involved in the study, and they have no known personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"355"}}